Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA
China-based Shanghai Kehua Bioengineering Co., Ltd. (KHB) (SHE: 002022) announced on July 23, 2025, that...
Company
Shenzhen Beimei’s TWYNEO Receives NMPA Clinical Trial Approval for Acne Treatment
Shenzhen Beimei Pharmaceutical Co., Ltd. announced on July 22, 2025, that its drug TWYNEO (tretinoin...
Chison Medical and Gates Foundation Collaborate on Innovative Ultrasound Equipment
China-based Chison Medical Technologies (SHA: 688358) announced on July 23, 2025, a partnership with the...
Shanghai MicroPort EP MedTech’s IceMagic Catheter Receives EU MDR Certification
Shanghai-based Shanghai MicroPort EP MedTech Co., Ltd. (SHA: 688351) announced on July 23, 2025, that...
CTTQ Doses First Patient in China for TQB6411 Phase I Clinical Trial
Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...
FDA-Approved Smile System Launches in Lecheng for ADHD Treatment
On July 22, 2025, the innovative non-pharmacological ADHD treatment medical device “Smile” (ADHD Transcutaneous Nerve...
Grand Pharma’s TLX591 Granted NMPA Approval for Phase III Prostate Cancer Trial
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that its innovative radiolabeled drug conjugate (RDC)...
Abbisko Therapeutics Completes First Patient Dosing for PRMT5×MTA Inhibitor ABSK131
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the completion of the first patient...
Novatim and ERIGEN Ink Licensing Pact for Dual-Target CAR-T Therapy KQ-2003
Novatim Immune Therapeutics (Zhejiang) Co., Ltd. announced a strategic cooperation with US-based biopharmaceutical company ERIGEN...
AusperBio Gains NMPA Approval for Phase III Trials of AHB-137 in Chronic Hepatitis B
Sino-US liver therapy developer AusperBio announced that the National Medical Products Administration (NMPA) has approved...
Sanofi to Acquire Vicebio Ltd for Up to USD 1.6 Billion, Advancing Next-Gen Vaccine Development
Vicebio Ltd has entered into an exclusive, definitive agreement to be acquired by France-based major...
AstraZeneca to Invest $50 Billion in US Manufacturing and R&D Expansion by 2030
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced plans to invest $50 billion in the United States by...
Genentech’s Astegolimab Shows Promising Results in Phase IIb COPD Trial
Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced the results of...
AstraZeneca’s FLAURA2 Study Confirms Osimertinib Combo’s Survival Benefit in NSCLC
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced the final overall survival (OS) results from the Phase III...
Livzon Pharma’s LZM012 Meets Phase III Endpoint for Psoriasis Treatment
China-Based Livzon Pharmaceutical Group, a holding subsidiary of Joincare Pharmaceutical (SHA: 600380) announced that the...
Simcere Zaiming Receives FDA Clearance for Phase I Trial of FGFR2b-Targeting ADC SIM0686
China-based Simcere Pharma’s (HKG: 2096) oncology arm, Simcere Zaiming Pharmaceutical, has secured U.S. FDA clearance...
Abbott Reports Q2 2025 Sales of USD 11.14 Billion, Led by Medical Devices Growth
Abbott (NYSE: ABT) reported global sales of USD 11.14 billion for the second quarter of...
DualityBio’s Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
Duality Biologics (HKG: 9606) announced that the US Food and Drug Administration (FDA) has granted...
Shanghai Pharma and Cutia Therapeutic Collaborate on Codon Biopharma’s Innovative Drug Distribution
China’s Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced the signing of...
Bio-Thera’s BAT4406F Gets NMPA Nod for MCD and FSGS Clinical Trials
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that its investigational drug, BAT4406F injection, has received approval...